Brachytherapy最新文献

{"title":"Wound complications and local recurrence do not differ when using interstitial brachytherapy versus external beam radiation therapy for soft tissue sarcoma","authors":"Martina Hale ,&nbsp;Precious Oyem ,&nbsp;Haley Prough ,&nbsp;Jacob G. Scott ,&nbsp;Zachary D. Burke ,&nbsp;Nathan W. Mesko ,&nbsp;Shauna R. Campbell ,&nbsp;Lukas M. Nystrom","doi":"10.1016/j.brachy.2025.06.003","DOIUrl":"10.1016/j.brachy.2025.06.003","url":null,"abstract":"<div><h3>PURPOSE</h3><div>Interstitial brachytherapy (BT) is an effective adjuvant treatment alternative to conventional external beam radiation therapy (EBRT) for soft tissue sarcoma (STS). However, little is known about how the wound healing profile of BT compares to that of EBRT.</div></div><div><h3>METHODS</h3><div>This is a comparative retrospective cohort study including patients receiving interstitial BT or conventional EBRT as adjuvant therapy to STS resection between 2015 and 2022. EBRT patients were included if their excised tumors had flat, planar geometries that would have made them good candidates for either EBRT or BT. Patient demographic parameters, wound closure techniques, wound complications, and oncologic outcomes were analyzed. Statistical analysis comparing wound complications and oncologic outcomes were assessed using chi-square tests.</div></div><div><h3>RESULTS</h3><div>Thirty-two patients received BT, and 23 similar patients met inclusion criteria who received EBRT. Baseline characteristics did not differ between groups. Twelve BT (37.5%) and 7 (30.4%) EBRT patients experienced some form of wound healing complication (<em>p</em> = 0.587) with necrosis being the most common complication. Seven (21.9%) BT patients and 6 (26.1%) EBRT patients required at least one reoperation to address complications (<em>p</em> = 0.717). Two BT and 1 EBRT patient developed local recurrence, and nine in each group developed metastasis.</div></div><div><h3>CONCLUSIONS</h3><div>Incidence of wound complications and oncologic outcomes did not statistically differ between BT and EBRT cohorts. In this institutional cohort of appropriately selected STS patients, BT was not inferior to EBRT with respect to wound complication rates and local control.</div></div>","PeriodicalId":55334,"journal":{"name":"Brachytherapy","volume":"24 5","pages":"Pages 791-798"},"PeriodicalIF":1.8,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144755421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Canadian brachytherapy experience: Results of the Canadian brachytherapy group national survey","authors":"Kevin Martell ,&nbsp;Mira Keyes ,&nbsp;Ericka Wiebe ,&nbsp;Eric Vigneault ,&nbsp;Amandeep Taggar","doi":"10.1016/j.brachy.2025.06.004","DOIUrl":"10.1016/j.brachy.2025.06.004","url":null,"abstract":"<div><h3>Purpose/Objective</h3><div>Brachytherapy (BT) techniques, skillsets and resource requirements have advanced over the past decade. This study aimed to characterize the current extent of BT availability, expertise and utilization in Canada.</div></div><div><h3>Materials and Methods</h3><div>A 68-question survey covering expertise, training, resources and future challenges to BT programs was created and sent to a single representative at each of the 36 of 49 radiotherapy centers in Canada identified to have an active BT program. Responses were then analyzed in aggregate.</div></div><div><h3>Results</h3><div>Thirty-one responses (response rate 86%) representing all provinces with at least 1 available BT program (9) were obtained. The median number of radiation oncologists practicing BT in each center was 5 (3-6); this represented 33% (24%–43%) of the workforce at each center. Thirty (97%) centers had at least 1 fellowship trained brachytherapist on site. Eleven (35%) respondent centers offered BT fellowship programs and 7 (64%) of those offered the nationally accredited brachytherapy designations at the end of training.</div><div>All 30 respondents (100%) offered BT treatment for endometrial cancer, 26 (87%) for cervical cancer, 25 (83%) for prostate cancer and 20 (67%) for vaginal cancer. In 2024, the median number of endometrial, cervical, prostate and vaginal cancers cases treated were 38 (22–50), 19 (7–33), 66 (41–138) and 1 (0–3), respectively. Sixteen (62%) respondents anticipated an increase in demand for BT resources within the next 5 years.</div></div><div><h3>Conclusion</h3><div>BT programs across Canada are supported by highly trained brachytherapists. BT programs most commonly treat gynecologic and genitourinary malignancies.</div></div>","PeriodicalId":55334,"journal":{"name":"Brachytherapy","volume":"24 5","pages":"Pages 663-669"},"PeriodicalIF":1.8,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HDR and PDR brachytherapy for facial nonmelanoma skin cancer: Outcome and toxicity assessment for 155 patients","authors":"Guillaume Virbel ,&nbsp;Kanta Ka ,&nbsp;Alexandre Escande ,&nbsp;Laurent Mortier ,&nbsp;Mael Barthoulot ,&nbsp;Xavier Liem ,&nbsp;Xavier Mirabel ,&nbsp;Eric F. Lartigau ,&nbsp;Abel Cordoba","doi":"10.1016/j.brachy.2025.06.011","DOIUrl":"10.1016/j.brachy.2025.06.011","url":null,"abstract":"<div><h3>Introduction</h3><div>Nonmelanoma skin cancer (NMSC), encompassing basal and squamous cell carcinomas, is among the most common malignancies worldwide. While surgery is the standard for early-stage lesions, it can be disfiguring for periorificial facial tumors.</div></div><div><h3>Objective</h3><div>To assess local and regional control, as well as toxicity outcomes, in patients with facial NMSC treated by brachytherapy at a comprehensive cancer center.</div></div><div><h3>Materials and Methods</h3><div>A total of 155 patients were included. Of these, 115 had squamous cell carcinoma and 34 had basal cell carcinoma. The lip was the most frequent site (103 cases), followed by the nose (49 cases). Brachytherapy was exclusive in 128 patients and adjuvant in 27.</div></div><div><h3>Results</h3><div>At 24 months, local and locoregional control rates were 93.9% (95% CI: 89.4–98.5%) and 90.3% (95% CI: 84.8–96.1%) respectively. No grade ≥3 late toxicity was observed.</div></div><div><h3>Conclusion</h3><div>Brachytherapy is a safe and effective organ-preserving option for facial NMSC, particularly in patients with anatomically complex lesions or contraindications to surgery.</div></div>","PeriodicalId":55334,"journal":{"name":"Brachytherapy","volume":"24 5","pages":"Pages 799-806"},"PeriodicalIF":1.8,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-dose-rate (HDR) brachytherapy boost in combination with external beam radiotherapy for localized prostate cancer: An evidence-based consensus statement","authors":"Sagar A. Patel ,&nbsp;Marisa Kollmeier ,&nbsp;Juanita Crook ,&nbsp;Daniel Krauss ,&nbsp;Gerard Morton ,&nbsp;Albert J. Chang ,&nbsp;Joelle Helou ,&nbsp;I-Chow Hsu ,&nbsp;Cynthia Menard ,&nbsp;Shyamal Patel ,&nbsp;Tyler Robin ,&nbsp;Peter J. Rossi ,&nbsp;Michael J. Zelefsky ,&nbsp;Mitchell R. Kamrava","doi":"10.1016/j.brachy.2025.06.005","DOIUrl":"10.1016/j.brachy.2025.06.005","url":null,"abstract":"<div><h3>PURPOSE</h3><div>This guideline presents evidence-based consensus recommendations for high-dose-rate (HDR) brachytherapy boost in combination with external beam radiotherapy (EBRT) for the primary treatment of localized prostate cancer.</div></div><div><h3>METHODS AND MATERIALS</h3><div>The American Brachytherapy Society convened a task force for addressing key questions concerning prostate HDR brachytherapy boost with EBRT for the primary treatment of localized prostate cancer. A comprehensive literature search was conducted to identify prospective and large retrospective studies involving HDR brachytherapy combined with EBRT. Outcomes of interest included biochemical and/or disease control, toxicity, patient-reported quality of life, and the role of androgen deprivation therapy.</div></div><div><h3>RESULTS</h3><div>HDR brachytherapy using Ir-192 in combination with EBRT is an appropriate treatment option for men with intermediate- and high-risk prostate cancer. CT, ultrasound, and/or MRI are imaging platforms that may be utilized for treatment planning and delivery. A single implant/fraction of 15 Gy or 2 implants/fractions of 9.5-11 Gy each are acceptable regimens in combination with EBRT at a dose equivalent of 45-50.4 Gy in 1.8-2.0 Gy fractions. The addition of HDR brachytherapy is expected to improve biochemical control compared with dose escalated EBRT alone. HDR brachytherapy boost is expected to achieve similar biochemical control outcomes as a low dose rate (LDR) brachytherapy boost. Androgen deprivation therapy is recommended for men with unfavorable intermediate and high-risk disease, with varying duration dependent on cancer risk. Use of an HDR brachytherapy technique, as opposed to LDR permanent seeds, has been shown to have less acute genitourinary (GU) and gastrointestinal (GI) toxicity following treatment.</div></div><div><h3>CONCLUSIONS</h3><div>For men with intermediate- and high-risk prostate cancer, HDR brachytherapy boost is a safe and effective technique for dose-escalation that can achieve superior biochemical control compared with EBRT alone, possibly with an improved GU and GI side effect profile compared with an LDR brachytherapy technique.</div></div>","PeriodicalId":55334,"journal":{"name":"Brachytherapy","volume":"24 5","pages":"Pages 644-662"},"PeriodicalIF":1.8,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144710286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life of patients submitted to radical radiochemotherapy for cervical cancer: Comparison of outcomes between 2D and 3D image guided brachytherapy","authors":"Layse Martins Gama ,&nbsp;Erica Aranha Suzumura ,&nbsp;Geovanne Pedro Mauro ,&nbsp;Patrícia Coelho de Soárez ,&nbsp;Heloisa de Andrade Carvalho","doi":"10.1016/j.brachy.2025.06.006","DOIUrl":"10.1016/j.brachy.2025.06.006","url":null,"abstract":"<div><h3>PURPOSE</h3><div>To assess QoL in patients with locally advanced cervical cancer treated with radical radiochemotherapy combined with either 2D or 3D brachytherapy, and to compare outcomes between both techniques.</div></div><div><h3>MATERIALS AND METHODS</h3><div>A cross-sectional analytical study was conducted from January 2019 to March 2020. EORTC QLQ-C30 and QLQ-CX24 questionnaires were applied at five time points: before treatment, and 1, 3, 6 and 12 months after treatment. Descriptive statistics, Pearson's chi-square, Fisher’s exact test and Bonferroni test were used (<em>p</em> ≤ 0.05).</div></div><div><h3>RESULTS</h3><div>Seventy six out of 82 patients completed all the assessments. The overall mean global health status significantly improved from 63.7 to 72.0 (<em>p</em> = 0.019), with no significant difference between the 2D and 3D brachytherapy groups (69.8 vs. 67.8; <em>p</em> = 0.672). All functional domains of the QLQ-C30 improved over time, including financial difficulties, regardless of the brachytherapy technique. Sexual activity increased significantly (2.5–32.4, <em>p</em> &lt; 0.0001), but also did sexual worry, menopausal symptoms, reduced sexual enjoyment, and vaginal dysfunction.</div></div><div><h3>CONCLUSIONS</h3><div>Overall improvement in global health and functioning were observed in patients with locally advanced cervical cancer, regardless of the brachytherapy technique used. Despite improved sexual activity, aspects of sexual dysfunction increased, highlighting the need for comprehensive, multidisciplinary care that includes sexual and psychological support, emphasizing the need for individualized care.</div></div>","PeriodicalId":55334,"journal":{"name":"Brachytherapy","volume":"24 5","pages":"Pages 721-728"},"PeriodicalIF":1.8,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144692756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A scoping review on the International State of Resident Brachytherapy Education","authors":"Joy Ogunmuyiwa ,&nbsp;Emily MacDuffie ,&nbsp;Beth Erickson ,&nbsp;Alina Sturdza ,&nbsp;Mira Keyes ,&nbsp;Mitchell Kamrava","doi":"10.1016/j.brachy.2025.05.005","DOIUrl":"10.1016/j.brachy.2025.05.005","url":null,"abstract":"<div><h3>INTRODUCTION</h3><div>Brachytherapy is a critical skill in the field of radiation oncology and remains an essential treatment modality in several disease sites. Multiple surveys conducted in the US suggest that a large proportion of residents do not feel comfortable performing several types of brachytherapy procedures upon graduation, highlighting a significant gap in training. To understand if similar issues exist outside the US, a scoping review was conducted to characterize the state of brachytherapy training internationally.</div></div><div><h3>METHODS</h3><div>An electronic search was conducted on PubMed on June 8, 2024 with a restriction on publication year prior to 2015 with the search terms “brachytherapy” and “resident.” Across the eight studies identified, a total of 1187 survey responses reported resident self-assessment of brachytherapy competence.</div></div><div><h3>RESULTS</h3><div>Surveys of residents from multiple continents report high variability in brachytherapy skill confidence with many techniques reporting less than 50% confidence. Surveys that also assessed barriers to brachytherapy training found that low caseload and lack of formal training or assessments were common issues.</div></div><div><h3>CONCLUSIONS</h3><div>These low rates of brachytherapy confidence across the globe are troubling and dedicated interventions, such as the establishment of competency-based assessments and effective simulation-based training, are needed to ensure that future radiation oncologists have the skills to deliver safe, high-quality patient care across the globe.</div></div>","PeriodicalId":55334,"journal":{"name":"Brachytherapy","volume":"24 5","pages":"Pages 814-819"},"PeriodicalIF":1.8,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144669108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sexual function and dosimetric relationships to neighboring neurovascular substructures among patients treated definitively with Pd-103 LDR prostate brachytherapy","authors":"Keara English ,&nbsp;Michael Roumeliotis ,&nbsp;Tanmay Singh ,&nbsp;Gayane Yenokyan ,&nbsp;Emerson Lee ,&nbsp;Todd McNutt ,&nbsp;Theodore DeWeese ,&nbsp;Daniel Y Song","doi":"10.1016/j.brachy.2025.06.001","DOIUrl":"10.1016/j.brachy.2025.06.001","url":null,"abstract":"<div><h3>PURPOSE</h3><div>To report sexual health outcomes related to Pd-103 prostate brachytherapy and evaluate dosimetric patterns to the nearby neurovascular structures. To assess potential relationships between dose to neurovascular substructures and erectile function outcomes in an institutional cohort treated definitively with Pd-103 LDR brachytherapy.</div></div><div><h3>MATERIALS AND METHODS</h3><div>The study utilized an IRB-approved database of men receiving low dose rate (LDR) prostate brachytherapy from 2014 to 2019 at our institution for definitive prostate cancer treatment. Patients routinely completed quality of life questionnaires at consultation and at subsequent follow up visits. Outcomes data related to sexual toxicity were evaluated based on the Sexual Health Inventory (SHIM) Questionnaire. Patients with pre-existing erectile dysfunction (SHIM &lt;17 or SHIM confidence score &lt;3) were excluded. The pudendal arteries, neurovascular bundles, subapical region, and penile bulb, were contoured on postimplant imaging and dosimetric data was analyzed. For all statistical comparisons, a student’s t-test was used with alpha of 0.05 indicating significance.</div></div><div><h3>RESULTS</h3><div>About 62 patients met criteria and were included in the analysis. All patients had either very low, low, favorable intermediate or unfavorable intermediate disease at diagnosis. Median follow-up was 5.5 years with total 380 individual questionnaires completed; 58 (93.5%) patients had follow-up greater than 2 years, and 28 (45.2%) patients had follow-up longer than 5 years. Mean baseline SHIM confidence score was 4.0 (SD 0.9). At most recent follow up, 34 patients (53%) had a SHIM confidence score greater than or equal to 3. Mean confidence SHIM for the cohort decreased from 4 to 3 after treatment and did not return to baseline over time. At the 6-month, 2-year, 4-year, and 5-year time points, the high dose NVB cohort demonstrated worse SHIM scores. At 5-year follow up, mean SHIM confidence was 2.2 ± 1.3 for the high dose group versus 3.6 ± 1.3 in the low dose group.</div></div><div><h3>CONCLUSIONS</h3><div>Erectile function appears to decrease following prostate brachytherapy with LDR Pd-103 seeds, demonstrated by a reduction in post procedural SHIM scores from baseline without recovery to preprocedure scores. The dose to adjacent neurovascular substructures other than NVBs is exceedingly low following Pd-103 LDR prostate brachytherapy and is unlikely to be the primary contributor to decreased sexual function related to this treatment modality. Out of the individual substructures, NVB dose may be the most critical.</div></div>","PeriodicalId":55334,"journal":{"name":"Brachytherapy","volume":"24 5","pages":"Pages 783-790"},"PeriodicalIF":1.8,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144669109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel approach for the treatment of a rare case of gingival metastasis in renal cell carcinoma using surface-mould brachytherapy","authors":"Sushant Sushant ,&nbsp;Ragavi Radhakrishnan ,&nbsp;VR Anjali ,&nbsp;KP Haresh ,&nbsp;Aparna Sharma ,&nbsp;Atul Sharma ,&nbsp;Seema Kaushal","doi":"10.1016/j.brachy.2025.05.002","DOIUrl":"10.1016/j.brachy.2025.05.002","url":null,"abstract":"<div><h3>BACKGROUND</h3><div>Gingival metastasis in renal cell carcinoma is rare and often results from widespread metastasis. Usually, when managed surgically, general anesthesia and extensive and morbid surgery are required. The present case describes one such mandibular gingival metastasis in a patient with RCC successfully managed using a conservative approach of mould brachytherapy.</div></div><div><h3>CASE DESCRIPTION</h3><div>A 54-year-old nonhypertensive, nondiabetic male with, a known case of clear cell RCC, on targeted therapy presented with a new proliferative lesion in the mandibular gingiva, with difficulty in chewing food, pain, and bleeding. On examination, an ulceroproliferative friable lesion was seen in the mandibular gingiva on the right side, approximately 3 × 2 cm, which bled on touch. Biopsy showed metastatic carcinoma, diffusely positive for Pan-cytokeratin and PAX8. He was treated with a palliative dose of 20 Gy in 5 Fr, delivered using surface mould high-dose-rate (HDR) brachytherapy twice a day, 6 hours apart along with Lenvatinib. The surface mould was made using an acrylic dental mould with attached interstitial catheters. The lesion started to regress after 1 month and completely disappeared after 3 months of radiation delivery, with a healthy pink gingiva.</div></div><div><h3>CONCLUSION</h3><div>Although oral metastasis of RCC has a poor prognosis due to the occurrence of concurrent disseminated metastases, HDR brachytherapy may be used as an easier and less invasive method for treating gingival metastasis. It can be sought as an alternative approach to surgery for treating gingival metastases in the future without compromising quality of life. Brachytherapy can be an essential tool for palliative treatment as well.</div></div>","PeriodicalId":55334,"journal":{"name":"Brachytherapy","volume":"24 5","pages":"Pages 828-832"},"PeriodicalIF":1.8,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144669107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of heterogeneity corrections for accelerated Monte Carlo-based treatment planning of plaque ocular brachytherapy","authors":"Oleksii Semeniuk ,&nbsp;Mark J. Rivard ,&nbsp;Robert A. Weersink","doi":"10.1016/j.brachy.2025.05.004","DOIUrl":"10.1016/j.brachy.2025.05.004","url":null,"abstract":"<div><h3>OBJECTIVE</h3><div>To develop and validate a practical method for accurate dose calculations of low-dose-rate brachytherapy treatment of eye tumors.</div></div><div><h3>METHODS</h3><div>Dose calculations of 16 mm Collaborative Ocular Melanoma Study (COMS) and 20 mm notched eye plaques with ¹²⁵I seeds were performed using the egs_brachy package of the EGSnrc Monte Carlo (MC). Several eye phantoms were modeled, including: (1) uniform phantoms made of only tumor (T), water, or vitreous body (VB) medium; (2) scaled water (SW) and scaled VB (SVB) distributions were derived by scaling the precomputed distributions for all-water and all-vitreous geometries by the relative energy absorption coefficient or each ocular structure to that of water or the vitreous body, respectively; (3) fully defined eye phantom with all structural materials defined; and 4) TG-43 calculations. Two contrasting tumor locations were modeled in this work. For investigation of dose distribution with standard plaques, the tumor was symmetrically located on the medial side of the eye. For the notched plaque, dose distributions were investigated with the tumor located posteriorly (abutting the optic nerve).</div></div><div><h3>RESULTS</h3><div>Compared to the fully-defined phantom calculations, all-water phantom calculations underestimated the tumor dose by 15–20%, while overestimating the lens and sclera dose. The optic nerve dose was predicted correctly. VB phantoms underestimated the tumor coverage by ∼3.5%, while T phantoms accurately predicted the target coverage. Both VB and T phantoms overestimated the organ-at-risk (OAR) doses more than all-water phantom. SW and SVB phantoms accurately predict both tumor and OAR doses within 4% of the complete phantom values for small volume metrics. Dose differences decreased to &lt; 2% to volumes &gt; 20%.</div></div><div><h3>CONCLUSION</h3><div>The dose scaling methodology provides a practical approach to account for ocular heterogeneity effects. This leads to accurate dosimetry, without computational penalties associated with patient-specific MC calculations. The methodology is found to be robust and applicable to both standard COMS and notched eye plaques of different sizes.</div></div>","PeriodicalId":55334,"journal":{"name":"Brachytherapy","volume":"24 5","pages":"Pages 754-762"},"PeriodicalIF":1.8,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144651515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dosimetric comparison between I-125 seed implantation and stereotactic body radiotherapy (SBRT) in patients with hepatic malignancies","authors":"Xu Zhu ,&nbsp;Bo Zhang ,&nbsp;Qi Kong ,&nbsp;Yuheng Li ,&nbsp;Pengfei Fan ,&nbsp;Dengbin Wu","doi":"10.1016/j.brachy.2025.06.002","DOIUrl":"10.1016/j.brachy.2025.06.002","url":null,"abstract":"<div><h3>PURPOSE</h3><div>This study aims to compare the dosimetric values of I-125 seed implantation with stereotactic body radiotherapy (SBRT) in the treatment of hepatic cancer patients.</div></div><div><h3>METHODS AND MATERIALS</h3><div>The study retrospectively analyzed 23 patients with hepatic malignancies treated with SBRT. A virtual I-125 seed implantation plan was simulated for comparison. For I-125 seed implantation, a prescription dose of 110 Gy was delivered to the gross tumor volume (GTV), corresponding to the planned target volume (PTV) in SBRT. Dosimetric values, including target coverage and dose to organs at risk (OARs), were compared using paired t-tests.</div></div><div><h3>RESULTS AND CONCLUSIONS</h3><div>The average PTV volume receiving 100% of the prescription dose was similar between the I-125 and SBRT groups (86.0% vs. 78.7%, <em>p</em> = 0.172). The I-125 group mean PTV V150% 62.9% ± 8.5%, while SBRT plans inherently restrict maximum PTV doses to ≤150% (resulting in 0% V150%). The mean minimum dose to PTV was significantly greater in the I-125 group than in the SBRT group (5562.49 cGy vs. 3289.69 cGy, <em>p</em> &lt; 0.01). Regarding OARs, the liver volume receiving ≥15 Gy was significantly lower in the I-125 group (274.67 cc vs. 485.72 cc, <em>p</em> &lt; 0.01), with similar trends observed for the small intestine, kidneys, stomach, and colon.</div><div>Dosimetric analysis revealed differences in dose distribution within the target volume and efficient OARs sparing using I-125 seed implantation compared with SBRT. Additional studies are required to examine the clinical relevance of these findings and determine whether combining these two methods may offer higher therapeutic benefit.</div></div>","PeriodicalId":55334,"journal":{"name":"Brachytherapy","volume":"24 5","pages":"Pages 820-827"},"PeriodicalIF":1.8,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144651514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}